ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0330

Assessing the Utility of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Impairment in Patients with SLE Using a Bayesian Item-Response Theory Model

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0223

Assessment During Rheumatology Fellowship After the Reforms in the French National Medical Curriculum: Has Anything Changed?

Professional Education Poster

1:00PM-3:00PM: Abstract Number: 0466

Assessment of Probability Scores to Predict Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0345

Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis

SLE – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0287

Association Between Short-Term Response to Upadacitinib Treatment and Long-Term Clinical Outcomes in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy

RA – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0034

Association of Anti-Tropomyosin Alpha-4 Autoantibodies with Cutaneous Manifestations in Juvenile Dermatomyositis

Pediatric Rheumatology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0091

Association of Area-Level Heat and Social Vulnerability with Recurrent Hospitalizations Among Individuals with Rheumatic Conditions

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: 0095

Association of Urban vs. Rural Residence with New DMARD Initiation in US Veterans with Active Rheumatoid Arthritis

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: 0027

Associations of Serum C3f with Selected Biomarkers and Radiographic and Clinical Features of Knee Osteoarthritis

Osteoarthritis and Joint Biology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0359

Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets

SLE – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0333

Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0149

Autoinflammatory Diseases Associated with NOD2 and Other Concurrent Genetic Mutations

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

1:00PM-3:00PM: Abstract Number: 0159

B Cell Phenotype in Adult Patients with Idiopathic Inflammatory Myositis (IIM) Before and After Belimumab

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0011

B Cell Subsets Contributing to the Autoreactive Plasma Cell Pool in Lyn-/- Mice

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

1:00PM-3:00PM: Abstract Number: 0019

Bacterial Peptidoglycan in Synovial Tissue at Time of Total Knee Arthroplasty Is Associated with Inflammatory Synovitis and Younger Patient Age

Osteoarthritis and Joint Biology – Basic Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].